Datapoint: Skyrizi Scores Crohn’s Disease Nod

The FDA last week approved AbbVie’s Skyrizi for the treatment of moderately to severely active Crohn’s disease. It will be the first IL-23 inhibitor in the Crohn’s market basket. Skyrizi was first approved in April 2019 as a treatment for severe plaque psoriasis, an indication for which it currently holds covered or better status for 98% of all insured lives under the pharmacy benefit. About 38% of insured lives have preferred access to Skyrizi, largely with utilization management restrictions applied.

SOURCE: MMIT Analytics, as of 6/22/22

0

0

0 Comments

0

0

• Datapoint